"NJRetina-Toms River is an eye care center & ophthalmology clinic with retina specialists & vitreoretinal surgeon ophthalmologists providing eye exams, diagnosis & treatment for retina diseases, problems & conditions including age related macular degeneration (AMD), macular diseases, diabetic retinopathy (DR), retinal vascular disease such as retinal vein occlusion & retinal artery occlusion, retinal detachment & tears, retinal membranes & macular holes. NJRetina specialists perform retina injections for AMD and Diabetic Retinopathy & laser photocoagulation treatment in our offices & a wide range of retina surgery including scleral buckle surgery, vitrectomy & pneumatic retinopexy for patients needing surgery to preserve or restore vision."

During the past decade, NJ Retina conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 4 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 2 clinical trials were completed. i.e. 66.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NJ Retina" #1 sponsor was "Apellis Pharmaceuticals, Inc." with 2 trials, followed by "Genentech, Inc." with 2 trials sponsored, "Hoffmann-La Roche" with 1 trials sponsored, "Long Island Vitreoretinal Consultants" with 1 trials sponsored and "Pfizer" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NJ Retina" #1 collaborator was "National Eye Institute (NEI)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "NJ Retina" are "Geographic Atrophy" (3 trials), "Macular Degeneration, Age-Related" (2 trials), "Age Related Macular Degeneration" (1 trials), "Age-Related Macular Degeneration" (1 trials) and "Age-Related Maculopathy" (1 trials). Many other conditions were trialed in "NJ Retina" in a lesser frequency.

Most popular intervention types in "NJ Retina" are "Drug" (9 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Galegenimab" (2 trials), "ranibizumab" (2 trials), "APL-2" (1 trials), "Avastin" (1 trials) and "Intravitreal Injections of 10 mg/mL Ranibizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "NJ Retina" are 10 trials for "All" genders.

Currently, there are NaN active trials in "NJ Retina". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in NJ Retina, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in NJ Retina, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".